Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2007

01-04-2007 | Original Article

Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Authors: Gloris Sánchez, Julio S. Castro, Soham Al Snih, Luísa Pérez Blanco, María H. Esteva, Ernesto García MacGregor, Marielena González, Ysabel Granados, Francisco Marín, Alexis Rosas, Antonio Tristano, Esther Chirinos, Luís Mundaraín, Gilberto Sanoja, Guisela Zambrano-Marín, Martín A. Rodríguez

Published in: Rheumatology International | Issue 6/2007

Login to get access

Abstract

A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan–Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.
Appendix
Available only for authorised users
Literature
1.
Weinblatt ME, Cobby JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822PubMedCrossRef
2.
Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuck KR, et al (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 35:129–137PubMedCrossRef
3.
Tugwell P, Bennet K, Gent M (1987) Methotrexate in rheumatoid arthritis. Ann Intern Med 107:358–366PubMed
4.
Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, Box JH, et al (1992) Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 35:849–856PubMedCrossRef
5.
Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1428PubMedCrossRef
6.
Thompson RN, Watts C, Edeelman J, Esdaile J, Russell AS (1984) A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11:760–762PubMed
7.
Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis-a controlled clinical trial. Arthritis Rheum 28:721–729PubMedCrossRef
8.
Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatism arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
9.
Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheumatism 35:498–502PubMedCrossRef
10.
Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662
11.
12.
Pincus T, Marcum SB, Callahan LF (1992) Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 19:1885–1894PubMed
13.
Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 40:984PubMedCrossRef
14.
Wolfe F (1995) The epidemiology of drug treatment failure in rheumatoid arthritis. Clin Rheumatol 9:619–632
15.
Cronstein BN (2004) Pharmacogenetics in the rheumatic diseases. Ann Rheum Dis 63(Suppl II):ii25–ii27PubMedCrossRef
16.
Alarcon GS, Tracy IC, Blackburn WD (1989) Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32:671–676PubMedCrossRef
17.
Kremer JM, Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29:822–831PubMedCrossRef
18.
Rau R, Schleusser B, Herborn G, Karger T (1998) Longterm combination therapy for refractory and destructive rheumatoid arthritis with mehotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to methotrexate monotherapy. J Rheumatol 25:1485–1492PubMed
19.
Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open long-term study of 191 cases. J Rheumatol 18:1323–1327PubMed
20.
Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of tradional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62:482–486PubMedCrossRef
21.
Goodman TA, Polisson RP (1994) Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 20:513–528PubMed
22.
van Ede AE, Laan RFJM, Blom HJ, De Abreu RA, van de Putte LBA (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 28:277–292
23.
Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44:61–66PubMedCrossRef
24.
25.
Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al (1999) Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225PubMedCrossRef
26.
Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D (1997) Toxicity profile of dual methotrexate combinations with gold, hydroxichloroquine, sulphasalazine and minocycline in rheumatoid arthritis. Rheumatol Int 17:49–53PubMedCrossRef
27.
Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatol 39:975–981CrossRef
28.
Fox RI (1998) Mechanism of action of Leflunomide in rheumatoid arthritis. J Rheumatol 53(Suppl 25):20–26
29.
Segal R, Yaaron M, Tartakovsky B (1990) Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 20:190–199PubMedCrossRef
30.
Kremer JL (1999) Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:14–26PubMedCrossRef
Metadata
Title
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis
Authors
Gloris Sánchez
Julio S. Castro
Soham Al Snih
Luísa Pérez Blanco
María H. Esteva
Ernesto García MacGregor
Marielena González
Ysabel Granados
Francisco Marín
Alexis Rosas
Antonio Tristano
Esther Chirinos
Luís Mundaraín
Gilberto Sanoja
Guisela Zambrano-Marín
Martín A. Rodríguez
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0261-x

Other articles of this Issue 6/2007

Rheumatology International 6/2007 Go to the issue

Original Article

Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis

Original Article

Assessment of sexual dysfunction in male patients with Ankylosing Spondylitis

Original Article

Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes

Original Article

Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis

Original Article

The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever

Original Article

Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits